NASDAQ: ABEOAbeona Therapeutics Inc Stock
$4.21+0.28 (+7.12%)
Updated Sep 29, 2023
ABEO Price
$4.21
Fair Value Price
$4.49
Market Cap
$104.22M
52 Week Low
$2.19
52 Week High
$5.80
P/E
-2.96x
P/B
11.15x
P/S
20.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.57M
Earnings
-$36.37M
Gross Margin
100%
Operating Margin
-1,004.26%
Profit Margin
-1,019.4%
Debt to Equity
4.73
Operating Cash Flow
-$43M
Beta
1.14
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ABEO Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABEO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABEO ($4.21) is undervalued by 6.17% relative to our estimate of its Fair Value price of $4.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ABEO ($4.21) is not significantly undervalued (6.17%) relative to our estimate of its Fair Value price of $4.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABEO due diligence checks available for Premium users.
Be the first to know about important ABEO news, forecast changes, insider trades & much more!
ABEO News
Valuation
ABEO fair value
Fair Value of ABEO stock based on Discounted Cash Flow (DCF)
Price
$4.21
Fair Value
$4.49
Undervalued by
6.17%
ABEO ($4.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABEO ($4.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABEO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.96x
Industry
13.67x
Market
12.37x
ABEO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.15x
Industry
5.09x
ABEO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABEO's financial health
Profit margin
Revenue
$3.5M
Net Income
-$16.7M
Profit Margin
-475.8%
ABEO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABEO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.6M
Liabilities
$44.2M
Debt to equity
4.73
ABEO's short-term assets ($44.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABEO's short-term assets ($44.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABEO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ABEO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.3M
Investing
$5.2M
Financing
$6.6M
ABEO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABEO vs Biotech Stocks
Abeona Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.